Parkinson’s disease affects more than 10 million people worldwide. Discover its causes, symptoms, and the latest innovations ...

Los Angeles Times readers give their thoughts on Bill Plaschke's poignant column on Parkinson's disease, the Dodgers and the ...

Bill Plaschke, the award-winning sports columnist and longtime "Around the Horn" panelist, announced his Parkinson's ...

For decades, researchers have wondered why some people with risky gene variants go on to develop Parkinson’s disease, while ...

Discover how Parkinson's disease begins in the gut, not the brain. Learn the early digestive warning signs that appear years ...

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Parkinson's disease is a progressive and common neurodegenerative condition, typically characterized by involuntary shaking, ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

MJFF co-founder and CEO Deborah W. Brooks read a letter of gratitude from Michael J. Fox for the support of the mission from ...

A team of researchers at UCLA has developed a high-tech diagnostic pen that can detect signs of Parkinson’s disease with over ...

Psilocybin therapy improved cognitive performance, reduced mood dysfunction, motor, and nonmotor symptoms in patients with Parkinson disease.